Selected article for: "chinese city and novel coronavirus"
Author: Derosa, Giuseppe; Maffioli, Pamela; D’Angelo, Angela; Di Pierro, Francesco
Title: Nutraceutical Approach to Preventing Coronavirus Disease 2019 and Related Complications
  • Cord-id: 4grqkn3u
  • Document date: 2021_6_28
    • ID: 4grqkn3u
    Snippet: INTRODUCTION: Several months ago, Chinese authorities identified an atypical pneumonia in Wuhan city, province of Hubei (China) caused by a novel coronavirus (2019-nCoV or SARS-CoV-2). The WHO announced this new disease was to be known as “COVID-19”. EVIDENCE ACQUISITION: Several approaches are currently underway for the treatment of this disease, but a specific cure remains to be established. EVIDENCE SYNTHESIS: This review will describe how the use of selected nutraceuticals could be helpf
    Document: INTRODUCTION: Several months ago, Chinese authorities identified an atypical pneumonia in Wuhan city, province of Hubei (China) caused by a novel coronavirus (2019-nCoV or SARS-CoV-2). The WHO announced this new disease was to be known as “COVID-19”. EVIDENCE ACQUISITION: Several approaches are currently underway for the treatment of this disease, but a specific cure remains to be established. EVIDENCE SYNTHESIS: This review will describe how the use of selected nutraceuticals could be helpful, in addition to pharmacological therapy, in preventing some COVID-19-related complications in infected patients. CONCLUSIONS: Even if a specific and effective cure for COVID-19 still has some way to go, selected nutraceuticals could be helpful, in addition to pharmacological therapy, in preventing some COVID-19-related complications in infected patients.

    Search related documents:
    Co phrase search for related documents
    • abdominal pain and acute ards respiratory distress syndrome: 1, 2, 3, 4
    • abdominal pain and lopinavir ritonavir: 1, 2, 3, 4
    • abdominal pain and low respiratory: 1, 2, 3, 4, 5, 6
    • abdominal pain and low respiratory tract: 1
    • abdominal pain and lung injury: 1, 2, 3, 4, 5
    • action mechanism and acute ards ali lung injury: 1, 2
    • action mechanism and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • action mechanism and adaptive immune response: 1, 2, 3
    • action mechanism and adaptive immune response innate: 1
    • action mechanism and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • action mechanism and lopinavir ritonavir treatment: 1, 2
    • action mechanism and low pathogenic: 1
    • action mechanism and low respiratory: 1
    • action mechanism and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29
    • active compound and acute ards ali lung injury: 1
    • active compound and acute ards respiratory distress syndrome: 1, 2
    • active compound and low pathogenic: 1
    • active compound and lung injury: 1, 2, 3, 4
    • active ingredient and acute ards respiratory distress syndrome: 1